Future trends of drug resistance and prospects of antiviral therapy

Doug Richman
International Drug Resistance Workshop
Johannesburg
24 October 2018
The principles of HIV drug resistance are well established (Darwinian evolution).

The mistakes and lessons learned in the developed world are being recapitulated in low and middle income countries.
HIV drug resistance is generated by one of two major mechanisms

- Acquired drug resistance following non-suppressive treatment (secondary resistance)

- Transmitted drug resistance (TDR) (primary resistance)

(PDR combines both TDR and resistance acquired from previous treatment, disclosed or not, after infection)

- Both mechanisms are too prevalent.
- Prevention strategies for these two mechanisms are completely different.
Diminishing drug resistance with superior regimens

Scherrer et al, CID, 2016
If resistance appears, it is often less fit resulting in lower viral loads.

How did this reduction in resistance with more expanded treatment happen?

- **Better drugs**
  - More potent and better half-lives (TDF/FTC, better PIs, integrase inhibitors)
  - More tolerable and less toxic
  - Introduction of several new compounds at the same time
  - Multiple fixed dose combinations

- **Better monitoring of failure and then use of drug resistance testing and better drugs for treatment failure**
All this happened before the availability of second generation integrase inhibitors.

Now, how do we approach the availability of TID or TFD
Virological suppression of individuals on ART in South Africa

- Data from 69,454 patients on 1st line ART
- 57 rural and urban clinics
- Monitoring according to SA guidelines
Low-level viremia increases risk of viral rebound

- Data from same dataset
- Association corrected for demographics, baseline CD4
- Risk also increased for confirmed failure and switch

Hermans et al, Lancet ID, 2018
In case of failure: Switch of ART is seriously delayed

• Observed clinical practice is delayed in comparison to guideline-recommended practice

• VL is measured repeatedly after rebound

• Switch is often postponed or not performed at all

Hermans et al, CROI, 2018
<table>
<thead>
<tr>
<th>Country</th>
<th>Study author</th>
<th>% with resistance</th>
<th>CI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cameroon</td>
<td>Zoufaly et al.</td>
<td>71%</td>
<td>54.1–84.6</td>
</tr>
<tr>
<td>Guinea</td>
<td>Diouara et al.</td>
<td>68%</td>
<td>47.6–84.1</td>
</tr>
<tr>
<td>Kenya</td>
<td>Hassan et al.</td>
<td>53%</td>
<td>38.8–66.3</td>
</tr>
<tr>
<td>Kenya</td>
<td>Kantor et al.</td>
<td>91%</td>
<td>78.7–97.5</td>
</tr>
<tr>
<td>Kenya</td>
<td>Koigi et al.</td>
<td>41%</td>
<td>26.3–56.7</td>
</tr>
<tr>
<td>Liberia</td>
<td>Loubet et al.</td>
<td>71%</td>
<td>55.9–83</td>
</tr>
<tr>
<td>Mali</td>
<td>Diouara et al.</td>
<td>93%</td>
<td>68–99.8</td>
</tr>
<tr>
<td>Mali</td>
<td>Fofana et al.</td>
<td>92%</td>
<td>83.5–96.5</td>
</tr>
<tr>
<td>Mauritania</td>
<td>Fall-Malick et al.</td>
<td>73%</td>
<td>59.7–83.6</td>
</tr>
<tr>
<td>Mozambique</td>
<td>Bila et al.</td>
<td>47%</td>
<td>30.4–64.5</td>
</tr>
<tr>
<td>Mozambique</td>
<td>Ruperez et al.</td>
<td>89%</td>
<td>77.7–95.2</td>
</tr>
<tr>
<td>Senegal</td>
<td>Diouara et al.</td>
<td>70%</td>
<td>49.8–86.2</td>
</tr>
<tr>
<td>Senegal</td>
<td>Diouara1 et al.</td>
<td>79%</td>
<td>65.3–88.9</td>
</tr>
<tr>
<td>Togo</td>
<td>Konou et al.</td>
<td>99%</td>
<td>96.6–99.9</td>
</tr>
</tbody>
</table>
The levels of acquired drug resistance requires addressing the causes

- The patient
  - adherence
- The prescribing care provider
  - selecting an optimal regimen
  - counseling the patient
- The drugs
  - Potency
  - tolerability
  - Pharmacokinetics
- The healthcare delivery system
  - Provide viral load monitoring with prompt turnaround and threshold <100 copies/mL
  - Provide assays for drug resistance (or drug levels).
  - Avoid stockouts
Rapid Suppression of HIV-1 RNA to < 50 copies/mL through Week 48 (Missing = Excluded Approach)

B/F/TAF vs. DTG/ABC/3TC or vs. DTG + F/TAF: displayed rapid viral suppression and non-inferior efficacy at Week 48.

AE=adverse event; DC=discontinuation; Other reasons= lost to follow-up, withdrew consent, investigator discretion, noncompliance, etc.)
Molepolole District

• 709 Chart reviews completed 78.9% (560) with viral load results at 12 months – All Cohorts:

  4 (<1%) VL >400 copies/mL
  6 (1%) LTFU
  3 (<1%) Deaths (2 TB related, 1 unknown)
  2 (<1%) Toxicity Grade 3

  **97.6% (548/560)**

  Viral Load <400 copies/mL at 12 months

Courtesy of Ava Avelos
## Switches to DTG Outcomes

<table>
<thead>
<tr>
<th>Reason for Switch</th>
<th>#</th>
<th>% VL &lt;400 6 months</th>
<th>% VL 400 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guidelines Simplification</td>
<td>33</td>
<td>10/11 (90.9%)</td>
<td>20/22 (90.9%)</td>
</tr>
<tr>
<td>Toxicities</td>
<td>173</td>
<td>85/87 (97.7%)</td>
<td>85/86 (98.8%)</td>
</tr>
<tr>
<td>Tx Failure</td>
<td>135</td>
<td>27/37 (72.9%)</td>
<td>94/98 (95.9%)</td>
</tr>
<tr>
<td>Totals</td>
<td>341</td>
<td>122/135 (90.3%)</td>
<td>199/206 (96.6%)</td>
</tr>
</tbody>
</table>

Courtesy of Ava Avelos
Measures are still needed to preserve the integrase class over time - 1

- Low level viremia ≠ treatment success
  - High threshold may be even more dangerous with DTG, since viruses resistant to DTG are often not very fit and viral load may remain low
- Delayed response to viral rebound puts individuals and society at risk
- Use tools (like viral load monitoring and objective adherence assessment) to generate insight in virological failure
Measures are still needed to preserve the integrase class over time - 2

- Avoid adding 1 new drug to a failing regimen
  - What is the risk of a switch from a failing regimen with TLE to TLD?
  - Surveillance in those who start DTG with unsuppressed viral load should be promptly initiated if resistance testing is not applied at switch
Acknowledgements

• Ava Alves
• Itrema team
  – Lucas Hermans
  – Annemarie Wensing
  – Monique Nijhuis